ROCKVILLE, Md.--(BUSINESS WIRE)--Neogenix Oncology, Inc. announced today that it will hold a conference call on Friday, April 8, at 11 a.m. Eastern Time to discuss the company’s 2010 financial results and business highlights. The financial results are also reported in Neogenix’s annual report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2011.
Investors and other interested parties are invited to listen to the call by dialing (760) 569-7676 and entering passcode 704306. The company is accepting questions in advance which will be addressed during the allocated sixty minute time period. An audio replay will be available at www.neogenix.com.
About Neogenix Oncology
Neogenix Oncology is a clinical stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, breast, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work at its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic test for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of the NEO-101 antibody in patients with metastatic pancreatic and colorectal cancer. NEO-201 and NEO-301 are in preclinical development towards IND submission. For more information, please visit www.neogenix.com.